SABINA EGLI

I'm a dynamic life scientist with hands-on experience in drug development, clinical trial management and a talent for navigating challenges. With strong problem-solving skills and proactive approach to new tasks, I'm known for adaptability, creativity, and results-oriented mindset. Committed to making meaningful contributions and advancing organizational goals.

• AI in pharma and biotech online course, Massachusetts Institute of Technology, 05/01/24, 07/31/24
• Scientific Writing Symposium Participant, Swiss Federal Institute of Technology, Zurich, 08/01/17
• Introductory Course in Laboratory Animal Science, LTK Module 1 (FELASA Category B) for Mice and Rats, University of Zürich, 01/01/16
• Certificate of Proficiency in English (ESOL), University of Cambridge, Grade C, 07/01/08, 08/31/08

• In vivo base editing of a pathogenic Eif2b5 variant improves vanishing white matter phenotypes in mice., 2024, Molecular Therapy, Böck D., Egli S., Schwank G.
• In vivo adenine base editing of PCSK9 in macaques reduces LDL-cholesterol levels., 2021, Nature Biotechnology, Rothgangl, Egli et al.
• Gene switch for l-glucose-induced biopharmaceutical production in mammalian cells., 2021, Biotechnol Bioengineering, Strittmatter T., Egli S., M.Fussenegger
• BOLD Opto-fMRI assay of the cortico-striatal circuits implicated in autism spectrum disorders and schizophrenia, 2019, Written report, F. Hoffmann - La Roche, Neuroscience Discovery

MIT Executive Education: AI in Pharma and Biotech